Obesity

Kansas

111 Obesity Trials near Kansas

Power is an online platform that helps thousands of Obesity patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female

96 Participants Needed

This trial aims to see if taking an omega-3 fatty acid supplement can help pregnant women with high triglyceride levels. High triglycerides can lead to having larger babies. The supplement might help control these fat levels in the blood. Omega-3 fatty acids, particularly DHA and EPA, have been studied for their potential benefits during pregnancy, including reducing preterm birth and improving fetal growth.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:0 - 39

40 Participants Needed

Apitegromab for Obesity

Norman, Oklahoma
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight or obesity
Stay on current meds

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65

100 Participants Needed

This trial is testing tirzepatide, a medication that helps people lose weight, to see if it can also help them keep the weight off. The study involves people who have already lost weight and need help maintaining it. Tirzepatide works by making people feel full and reducing their appetite. Tirzepatide has been effective in helping people lose weight and manage blood sugar levels.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

400 Participants Needed

CagriSema for Obesity

Norman, Oklahoma
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

600 Participants Needed

The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

905 Participants Needed

Orforglipron for Obesity

Norman, Oklahoma
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

300 Participants Needed

This trial tests if a new combination of two drugs, given regularly, helps people lose weight better than another treatment. It targets individuals needing to lower their body weight by helping them feel less hungry and manage their weight. Two different drugs are being investigated as options for weight management.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

809 Participants Needed

CagriSema for Obesity

Norman, Oklahoma
This trial tests how well different treatments help people with excess body weight lose weight. Participants will receive one of four treatments through regular injections. The study will last over a year, followed by a period to observe long-term effects.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

3400 Participants Needed

Aleniglipron for Obesity

Norman, Oklahoma
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

71 Participants Needed

GSBR-1290 for Obesity

Norman, Oklahoma
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

220 Participants Needed

RO7795081 for Obesity

Norman, Oklahoma
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for chronic weight management in adult participants with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

340 Participants Needed

NNC0519-0130 for Obesity

Norman, Oklahoma
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

355 Participants Needed

This trial is testing if stricter blood sugar targets can help overweight and obese pregnant women with gestational diabetes have healthier pregnancies. By aiming for lower blood sugar levels, the study hopes to reduce complications for both mothers and babies. The trial will also check if this approach is safe and cost-effective.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45
Sex:Female

828 Participants Needed

The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

409 Participants Needed

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

240 Participants Needed

The study examines patient weight loss and maintenance, associated predictors (patient health characteristics and demographics), and contextual factors in the practice environment that influence the intervention's adoption, implementation, and sustainability. This will be achieved through a mixed methods implementation study including collection and analysis of de-identified clinical data, surveys, observations, and interviews.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

100000 Participants Needed

This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

285 Participants Needed

Retatrutide for Obesity

Springfield, Missouri
This trial is testing a weekly medication called retatrutide. It aims to help people who are overweight or obese and have knee osteoarthritis. The study will last over a year to see if the medication is safe and effective.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

405 Participants Needed

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

800 Participants Needed

Why Other Patients Applied

"I have tried to lose weight, but as I get older, it becomes harder and harder. I have lost weight in the past through diet and exercise, but it has been more difficult to accomplish as I age."

JP
Obesity PatientAge: 44

"I have a heart condition, and my fat is all in my chest, surrounding my heart. It's hard for me to exercise because my legs are thin and the upper body weight is too much — putting strain on my leg joints. It’s a vicious cycle. I am also post-menopausal, which adds additional weight loss difficulty. I also have stress with being a full time caregiver for my mom. I'm interested in trying a clinical trial."

DK
Obesity PatientAge: 56

"I am applying for my daughter. She turns 12 this year and is overweight. She's 5'4" and 176 pounds. Would be great to enroll her in a clinical trial to see if this form of care could work for her. Realize that there's no guarantee, but I support her and we'd like to give it a try."

MW
Parent of PatientAge: 46

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I need to lose weight because it's affecting my knees. I've already had a knee replacement and the second one is happening on the left knee in a few months. I've participated in a study in the past for a skin-related issue, and had a good experience. That's why I'm interested in joining a study for wieght loss."

KI
Obesity PatientAge: 69

Orforglipron for Obesity

West Des Moines, Iowa
This trial will test a daily pill called orforglipron to see if it helps people who are overweight or obese and have type 2 diabetes lose weight. The study will last over a year and involve multiple visits.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1500 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Obesity clinical trials in Kansas pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Obesity clinical trials in Kansas work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Obesity trials in Kansas 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Kansas for Obesity is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Kansas several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Obesity medical study in Kansas?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Obesity clinical trials in Kansas?

Most recently, we added Cagrilintide + CagriSema for Childhood Obesity, EAT Family Style + Better Kid Care for Healthy Eating and NNC0662-0419 for Obesity to the Power online platform.

What is the new treatment for obesity?

The “new” treatments are weekly injections of GLP-1–based drugs such as semaglutide (Wegovy) and the dual GIP/GLP-1 drug tirzepatide (Zepbound), which curb appetite and slow stomach emptying; in large trials they helped adults lose roughly 15-22 % of their starting weight over 12–18 months when combined with diet and exercise. They are prescription-only, must be used long-term to keep the weight off, and while most side-effects are mild stomach upset, they can be expensive and require close medical follow-up—so you and your clinician should weigh these pros and cons against other options like older pills, bariatric surgery, and structured lifestyle programs.

How much do I get paid for a clinical trial?

There is no single rate, but in the U.S. healthy-volunteer Phase I studies usually pay about $75–$150 for a short outpatient visit or $300–$500 per overnight, adding up to roughly $1,500–$6,000 for a multi-day study; later-phase trials for people who already have the illness typically offer a smaller stipend—often $25–$100 per visit—plus travel reimbursement. Amounts are set case-by-case by the study sponsor and ethics board, based on the time you give up, the inconvenience or discomfort involved (blood draws, overnight stays, special diets), and any out-of-pocket costs, and they must be prorated so you can stop at any time and still receive payment for the visits you’ve completed.

How much weight can you lose with ESG surgery?

Large studies find that people lose roughly 15–20 % of their starting weight after endoscopic sleeve gastroplasty—about 30–50 lb if you begin at 200–250 lb—and most keep the bulk of that off for at least two years when they stay in a structured nutrition and activity program. Your exact result can be higher or lower depending on your initial BMI, how closely you follow the dietary and lifestyle plan, and whether you attend regular follow-up visits with the bariatric team.

What weight is considered obese?

For adults, obesity starts at a body-mass index (BMI) of 30 kg/m²—so take your height in metres, square it, and multiply by 30 to see the weight cut-off. Example: 5′4″ (1.63 m) → 1.63² × 30 ≈ 88 kg / 194 lb; 6′0″ (1.83 m) → 1.83² × 30 ≈ 102 kg / 225 lb. BMI is only a quick gauge—muscle mass, ethnicity, waist size, and other health factors matter too—so use it as a starting point and confirm risks with your healthcare professional.

Who is eligible for tirzepatide?

Tirzepatide is eligible for adults in two settings: (1) as Mounjaro to improve blood-sugar control in type-2 diabetes, and (2) as Zepbound for weight management if you have obesity (BMI ≥ 30) or are overweight (BMI ≥ 27) with at least one related condition such as high blood pressure, abnormal cholesterol, sleep apnea, heart disease, or type-2 diabetes. You are NOT a candidate if you’re pregnant, under 18, or have a personal or family history of medullary thyroid cancer or MEN-2; your doctor will also screen for issues like pancreatitis, severe stomach problems, or other risks before prescribing. In short, meeting the diabetes or weight criteria and having no major contraindications makes you a potential candidate, but final approval comes after a thorough medical review.

What tests are done for unexplained weight gain?

Doctors usually start with a history and physical exam, then order a small “baseline” panel—complete blood count, comprehensive metabolic panel (kidney + liver), fasting glucose/HbA1c, cholesterol, thyroid-stimulating hormone, and a pregnancy test in women of child-bearing age. If exam findings point to a specific cause, they add focused tests: e.g., cortisol or prolactin for suspected hormone tumors, sex-hormone and ultrasound for possible PCOS, heart or kidney studies for fluid retention, or imaging of the pituitary/adrenal glands. In short, everyone gets the core labs, and any further blood work or scans are chosen only when your symptoms or medications suggest a particular problem.

Can a morbidly obese person lose weight without surgery?

Yes. Rigorous studies show that people with class III (“morbid”) obesity can shed 6-8 % of their starting weight through weekly lifestyle-coaching programs, and often 15-20 % when the same program is paired with new once-a-week injections such as semaglutide (Wegovy) or tirzepatide (Zepbound); endoscopic sleeve procedures add another non-surgical option in the same range. Because even a 5-10 % loss markedly improves blood pressure, diabetes and sleep-apnea, doctors usually start with dietitian-guided eating plans, gradual activity and behaviour counselling, then add medication if weight hasn’t dropped by about 5 % after three months—saving surgery for those who still need more help.

How to get rid of fat deposits on legs?

You can’t melt fat from your legs alone, so aim for gradual overall weight loss (a modest calorie deficit built around whole foods) while doing both full-body cardio and leg-strength exercises such as squats or lunges 2-3 times a week—the combo burns calories and builds muscle that makes legs look firmer as fat comes off. If your legs stay disproportionately large, painful or bruise easily, ask a clinician about lipedema or other medical causes, because lifestyle changes help most people but specialised treatment is sometimes needed.

How to get Ozempic for weight loss?

Ozempic (semaglutide) can be prescribed for weight loss, but it is technically an off-label use; most clinicians instead start with the weight-loss version of the same drug, Wegovy. To pursue either one, confirm you meet typical criteria (BMI ≥30, or ≥27 with a weight-related condition), then see a primary-care doctor, endocrinologist, or an obesity-medicine/telehealth service that can review your labs, rule out contraindications, and submit any required prior-authorization to your insurer or the manufacturer’s savings program. Expect a gradual dose-escalation schedule, routine follow-ups for side-effects such as nausea, and the need to pair the medication with diet and activity changes to maintain the ~15 % average weight loss seen in clinical trials.

Which drink is good for belly fat loss?

No drink can “melt” belly fat on its own; losing abdominal fat still comes down to taking in fewer calories than you burn. The most studied helpers are plain water (pre-meal water can curb appetite), unsweetened green tea or black coffee (their caffeine and, for green tea, catechins give a small metabolic boost). Choose these without added sugar, pair them with balanced meals and regular exercise, and they can support—rather than drive—belly-fat loss.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security